Starpharma’s big breakthrough in cancer treatment

Alan Kohler here with today’s CEO and it’s Jackie Fairly the CEO of Starpharma. Now Starpharma has a long-standing, loyal group of shareholders/supporters that have maintained the share price at about $1.30 for a while. It’s got a very solid market capitalisation for a company that doesn’t make any money. It’s almost five hundred million dollars and still losing money. It’s got two main products. One is what’s called VivaGel which is a treatment for bacterial vaginosis which is a common problem for women. It’s on sale in Australia as Fluerstat. It’s $35-45 per treatment. They’ve priced it to sell a lot. It’s

Become a TCI Community Member Now

Stay up to date and make better informed decisions.
Get access to all this exclusive content and so much more every week!

  • $1 for the first month
  • $25/month membership
  • Cancel anytime, no lock in contract
  • Access to Private Facebook group
  • Smartphone App (coming soon)